245 related articles for article (PubMed ID: 33215343)
1. Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of chemotherapeutic management and antiangiogenic treatment of newly diagnosed glioblastoma in adults.
Redjal N; Nahed BV; Dietrich J; Kalkanis SN; Olson JJ
J Neurooncol; 2020 Nov; 150(2):165-213. PubMed ID: 33215343
[TBL] [Abstract][Full Text] [Related]
2. The role of radiation therapy in treatment of adults with newly diagnosed glioblastoma multiforme: a systematic review and evidence-based clinical practice guideline update.
Ziu M; Kim BYS; Jiang W; Ryken T; Olson JJ
J Neurooncol; 2020 Nov; 150(2):215-267. PubMed ID: 33215344
[TBL] [Abstract][Full Text] [Related]
3. Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of emerging developments in the management of newly diagnosed glioblastoma.
Farrell C; Shi W; Bodman A; Olson JJ
J Neurooncol; 2020 Nov; 150(2):269-359. PubMed ID: 33215345
[TBL] [Abstract][Full Text] [Related]
4. The role of initial chemotherapy for the treatment of adults with diffuse low grade glioma : A systematic review and evidence-based clinical practice guideline.
Ziu M; Kalkanis SN; Gilbert M; Ryken TC; Olson JJ
J Neurooncol; 2015 Dec; 125(3):585-607. PubMed ID: 26530261
[TBL] [Abstract][Full Text] [Related]
5. Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience.
Akiyama Y; Kimura Y; Enatsu R; Mikami T; Wanibuchi M; Mikuni N
World Neurosurg; 2018 May; 113():e508-e514. PubMed ID: 29476996
[TBL] [Abstract][Full Text] [Related]
6. Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of cytotoxic chemotherapy and other cytotoxic therapies in the management of progressive glioblastoma in adults.
Germano IM; Ziu M; Wen P; Ormond DR; Olson JJ
J Neurooncol; 2022 Jun; 158(2):225-253. PubMed ID: 35195819
[TBL] [Abstract][Full Text] [Related]
7. Cytoreductive surgery in the management of newly diagnosed glioblastoma in adults: a systematic review and evidence-based clinical practice guideline update.
Domino JS; Ormond DR; Germano IM; Sami M; Ryken TC; Olson JJ
J Neurooncol; 2020 Nov; 150(2):121-142. PubMed ID: 33215341
[TBL] [Abstract][Full Text] [Related]
8. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
9. Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of targeted therapies and immunotherapies in the management of progressive glioblastoma.
Winograd E; Germano I; Wen P; Olson JJ; Ormond DR
J Neurooncol; 2022 Jun; 158(2):265-321. PubMed ID: 34694567
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic therapy for high-grade glioma.
Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
[TBL] [Abstract][Full Text] [Related]
11. Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy.
Affronti ML; Heery CR; Herndon JE; Rich JN; Reardon DA; Desjardins A; Vredenburgh JJ; Friedman AH; Bigner DD; Friedman HS
Cancer; 2009 Aug; 115(15):3501-11. PubMed ID: 19514083
[TBL] [Abstract][Full Text] [Related]
12. Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.
Ohno M; Miyakita Y; Takahashi M; Igaki H; Matsushita Y; Ichimura K; Narita Y
Radiat Oncol; 2019 Nov; 14(1):200. PubMed ID: 31718669
[TBL] [Abstract][Full Text] [Related]
13. The role of neuropathology in the management of newly diagnosed glioblastoma: a systematic review and evidence-based clinical practice guideline.
Velázquez Vega JE; Brat DJ; Ryken TC; Olson JJ
J Neurooncol; 2020 Nov; 150(2):143-164. PubMed ID: 33215342
[TBL] [Abstract][Full Text] [Related]
14. Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.
Shields LB; Shelton BJ; Shearer AJ; Chen L; Sun DA; Parsons S; Bourne TD; LaRocca R; Spalding AC
Radiat Oncol; 2015 Oct; 10():222. PubMed ID: 26520780
[TBL] [Abstract][Full Text] [Related]
15. Results of phase I study of a multi-modality treatment for newly diagnosed glioblastoma multiforme using local implantation of concurrent BCNU wafers and permanent I-125 seeds followed by fractionated radiation and temozolomide chemotherapy.
McPherson CM; Gerena-Lewis M; Breneman JC; Warnick RE
J Neurooncol; 2012 Jul; 108(3):521-5. PubMed ID: 22467191
[TBL] [Abstract][Full Text] [Related]
16. The role of imaging for the management of newly diagnosed glioblastoma in adults: a systematic review and evidence-based clinical practice guideline update.
Lundy P; Domino J; Ryken T; Fouke S; McCracken DJ; Ormond DR; Olson JJ
J Neurooncol; 2020 Nov; 150(2):95-120. PubMed ID: 33215340
[TBL] [Abstract][Full Text] [Related]
17. Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review.
Ashby LS; Smith KA; Stea B
World J Surg Oncol; 2016 Aug; 14(1):225. PubMed ID: 27557526
[TBL] [Abstract][Full Text] [Related]
18. MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers.
Gutenberg A; Bock HC; Brück W; Doerner L; Mehdorn HM; Roggendorf W; Westphal M; Felsberg J; Reifenberger G; Giese A
Br J Neurosurg; 2013 Dec; 27(6):772-8. PubMed ID: 23662801
[TBL] [Abstract][Full Text] [Related]
19. Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials.
Carlson JA; Reddy K; Gaspar LE; Ney D; Kavanagh BD; Damek D; Lillehei K; Chen C
J Neurooncol; 2015 Jun; 123(2):251-7. PubMed ID: 25920710
[TBL] [Abstract][Full Text] [Related]
20. Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer.
Shapira-Furman T; Serra R; Gorelick N; Doglioli M; Tagliaferri V; Cecia A; Peters M; Kumar A; Rottenberg Y; Langer R; Brem H; Tyler B; Domb AJ
J Control Release; 2019 Feb; 295():93-101. PubMed ID: 30605703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]